Search the Newsreel

Cellebrite DI (NASDAQ:CLBT) Sets New 52-Week Low - Time to Sell?

Cellebrite DI (NASDAQ:CLBT) shares recently fell to a new 52-week low of $10.55, despite previously closing at $15.25. While insider selling totaling $2.48 million occurred over the last three months, analysts maintain a "Moderate Buy" consensus with an average price target of $21.80. Institutional …

Cellebrite DI Q2 Earnings Call Highlights

S&P 500-Titel United Parcel Service-Aktie: So viel hätten Anleger mit einem Investment in United Parcel Service von vor 10 Jahren verloren

Celcuity earnings loom as breast cancer drug approval fuels optimism

Celanese Corp SVP & General Counsel Acquires 600 Shares in Open Market Transaction

Ashley B. Duffie, Senior Vice President and General Counsel of Celanese Corp (NYSE:CE), purchased 600 shares of the company's common stock on August 11, 2026, at $45.6 per share. This open market transaction increases Duffie's direct ownership to 31,925 shares, with an additional 691.4868 …

Earnings call transcript: Cellectar narrows focus on WM as Q2 2026 loss widens

Cellectar Biosciences reported a wider-than-expected Q2 2026 loss of $0.57 per share, but its stock rose in premarket trading due to a stronger cash position and clinical progress for its lead drug, iopofosine I-131, in Waldenstrom’s macroglobulinemia (WM). The company secured up to $140 …

Accelerant Holdings (ARX) Reports Q2 Earnings: What Key Metrics Have to Say

Suzano S.A. (NYSE: SUZ) earnings: profit drops as cash flow stays strong

Suzano S.A. reported a significant drop in net income to R$1.8 billion in Q2 2026, down from R$5.0 billion a year earlier, primarily due to a weaker net financial result and higher costs. Despite this, the company maintained strong adjusted free cash flow of …

Cellebrite Appoints Shiven Ramji CEO as Company Sharpens Product Strategy

Cellebrite DI Ltd. has appointed Shiven Ramji as its new CEO, succeeding Thomas E. Hogan, to sharpen its product strategy with a focus on AI and new growth opportunities. Ramji, previously president of products and technology, will lead the company's expansion beyond digital forensics …

Earnings To Watch: Xcel Brands Inc (XELB) Q2 2026 -- GF Value Se

Xcel Brands Inc (XELB) is scheduled to release its Q2 2026 earnings on August 14, 2026, with revenue and earnings per share estimates showing recent declines. Analysts project an average target price of $4.00, implying a 292.16% upside, while GuruFocus's GF Value suggests an …

Suzano Posts Strong 2Q26 Cash Generation Despite Higher Costs and Rising Leverage

Dev Accelerator Posts Q1 FY27 Earnings Call Audio for Investor Access

Excel Industries Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Celsius (CELH) Q2 2026 Earnings Call Transcript

Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins

Omnicell (OMCL) has raised its 2026 earnings outlook after a strong second quarter, though a significant portion of the profit improvement came from a one-time tariff refund. The company faces increased memory-chip costs expected to impact gross margins but plans to leverage cost control …

Suzano (SUZ) boosts Q2 2026 free cash flow to R$3.3B amid higher prices

Suzano S.A. reported a significant increase in adjusted free cash flow to R$3.3 billion in Q2 2026, driven by higher prices and volumes, despite a year-on-year decline in Adjusted EBITDA. The company's sales volume rose to 2.9 million tons, supported by strong Brazilian operations. …

Soleus Capital group (VCEL) discloses 2.8% Vericel ownership under 5% level

Soleus Capital Master Fund, L.P. and associated entities have reported a beneficial ownership of 2.8% in Vericel Corp (VCEL) common stock, totaling 1,458,882 shares. This updated disclosure, filed on an amended Schedule 13G, places their ownership below the 5% threshold, indicating passive investment. All …

Accelerant Holdings (ARX) Tops Q2 Earnings and Revenue Estimates

Cellebrite DI Ltd. (CLBT) Q2 Earnings and Revenues Miss Estimates

Cellebrite DI Ltd. (CLBT) reported Q2 earnings of $0.11 per share, missing the Zacks Consensus Estimate of $0.12, and revenues of $131.14 million, which also fell short of expectations. The company's shares have declined by 15.4% year-to-date, contrasting with the S&P 500's gain, and …

Accelerant Holdings (NYSE: ARX) sharply lifts Q2 2026 profit and revenue

Cellebrite (CLBT) CRO sells 411 shares to cover RSU tax obligations

Cellebrite DI Ltd.'s Global Chief Revenue Officer, Jewell Marcus, sold 411 ordinary shares on August 12, 2026, at a weighted average price of $16.0678 per share. This transaction was executed to cover tax obligations related to the vesting of Restricted Stock Units (RSUs) granted …

Accelerant Holdings (ARX) agrees to $20.25-per-share Thoma Bravo buyout after strong Q2

Accelerant Holdings (ARX) has entered into a definitive agreement to be acquired by Thoma Bravo in an all-cash merger valued at over $4 billion. Shareholders will receive $20.25 per share, representing a 49% premium to the August 12, 2026 closing price. The deal, supported …

Accelerant, Harmonic surge, Cisco slides premarket on margin outlook

Investing.com - U.S. stock index futures pointed higher on Thursday, as investors digested fresh corporate earnings and deal news while continuing to assess the outlook for inflation and interest rates. By 06:19 ET (10:19 GMT), the Dow futures contract had risen by 112 points, …

Cellectar Reports Q2 2026 Results, Strengthened Cash Positions Supports Oncology Pipeline

(RTTNews) - Cellectar Biosciences, Inc. (CLRB) reported second-quarter 2026 results, highlighting increased R&D investment and a stronger balance sheet compared to the prior year. The company advanced its oncology pipeline with progress in pivotal and early-stage trials, while preparing for a Phase 3 confirmatory …

ACCELERANT HOLDINGS ($ARX) Releases Q2 2026 Earnings

Cellectar Biosciences (CLRB) Q2 loss hits $6.9M as cash reaches $34M

Cellectar Biosciences reported a net loss of $6.9 million for Q2 2026, an increase from $5.4 million in Q2 2025, driven by higher R&D expenses. The company's cash and cash equivalents rose to $34.0 million, up from $13.2 million at the end of 2025, …

Cellectar Prepares ~100-Patient-Per-Arm Trial, Plans 2027 FDA Filing

Cellectar Biosciences reported its Q2 2026 financial results, including a $6.9 million net loss, and provided significant corporate updates. The company is advancing its radiotherapeutic pipeline, most notably initiating site activation for a Phase 3 confirmatory trial for iopofosine I 131 in Waldenström macroglobulinemia, …

Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Cellectar Biosciences announced its second-quarter 2026 financial results and provided a corporate update, highlighting progress in its oncology pipeline. Key developments include the initiation of site activation for a confirmatory Phase 3 study of iopofosine I 131 in Waldenström Macroglobulinemia (WM), with an NDA …

CELLEBRITE DI ($CLBT) Releases Q2 2026 Earnings

This article first appeared on GuruFocus. ARR: Increased 21% to $508 million, missing the bottom end of guidance. Revenue: $131 million, up 16% year-over-year. Subscription Revenue: $119.5 million, up 16%, representing 91% of total revenue. Gross Profit: Increased 16% to $112 million, with a …

Cellebrite Appoints Shiven Ramji Chief Executive Officer, Succeeding Thomas E. Hogan

Cellebrite DI Ltd. announced that Shiven Ramji has been appointed Chief Executive Officer, succeeding Thomas E. Hogan, as part of a planned transition. The company also reported its second-quarter 2026 financial results, with total Annual Recurring Revenue (ARR) of $507.8 million, up 21% year-over-year, …

Cellebrite DI Ltd. (CLBT) Tops Q2 EPS by 4c ; Offers Guidance

Cellebrite DI Ltd. (CLBT) reported Q2 EPS of $0.11, exceeding analyst estimates by $0.04, with revenue of $131.14 million. The company provided Q3 2026 revenue guidance of $145-148 million and full-year 2026 revenue guidance of $550-560 million, both slightly below consensus estimates.

Accelerant to Go Private in $4.4B Deal with Thoma Bravo

Accelerant has agreed to be taken private by private-equity firm Thoma Bravo in a deal valued at over $4 billion. Shareholders will receive $20.25 per share in cash, representing a 49% premium over the company's August 12 closing price. The transaction is anticipated to …

Cellectar Biosciences (CLRB) raises $31.7M, flags going concern risk

MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update

MediWound Ltd. EscharEx® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under its BARDA Contract for NexoBrid® Second Quarter Revenue of $3.1 Million; Full-Year 2026 Revenue Guidance of $24–26 …

Cellectar Biosciences 6M 2026: Net loss $(12.6M), Diluted EPS $(1.52) — 10-Q Summary

Cellectar Biosciences reported a consolidated net loss of $(12.6M) and diluted loss per share of $(1.52) for the six months ended June 30, 2026. The company remains pre-revenue but achieved clinical milestones including positive Phase 2 results for CLOVER WaM and FDA Breakthrough Therapy …

Hexcel (HXL), What Is Behind The Fresh Attention?

Hexcel (HXL) has recently garnered attention, with its stock closing at $102.31, reflecting strong recent performance over one year. While one valuation narrative suggests the stock is modestly overvalued at $98.93, another Discounted Cash Flow model indicates a value of $138.03, implying it could …